Clinical Trial Update: Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the biological efficacy of HerpV vaccine with QS-21 for recurrent genital herpes due to HSV-2; study completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Herpes
• Herpes Simplex Virus Type Infection

Drugs mentioned

• HerpV vaccine with QS-21 (HerpV vaccine with QS-21)

Snippet

Sponsor: Agenus Inc. | Conditions: Herpes Simplex Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2021-07-13